LinkedIn
Facebook
Ipsen’s financial results for the first nine months of 2025
- 06 October 2025 - 0 mins read
22 October 2025
22 October 2025
Ipsen Q3 Results Call
Ipsen’s financial results for the first nine months of 2025 were published on 22 October 2025.
An investor and analyst conference call took place on the same day.
Webcast RecordingAbout Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries, and our partnerships around the world, enable us to bring medicines to patients in more than 100 countries.
Ipsen in brief
Discover Ipsen, our medicines and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: khalid.deojee@ipsen.com
How useful was this post?
Click on a star to rate it!
Key contacts
Henry Wheeler
Vice President, Investor Relations
Khalid Deojee
Senior Manager, Investor Relations
